By Fineline Cube 
China-based Innovent Biologics Inc., (HKG: 1801) and JD Health International Inc., (HKG: 6618) have officially entered into a strategic collaboration agreement. The partnership aims to deepen cooperation across drug supply, omni-channel sales, and digital marketing. This collaboration leverages the strengths of both companies to provide consumers with diverse, high-quality pharmaceutical products and healthcare services.
Innovent Biologics’ Market Presence
As a leading Chinese biopharmaceutical company, Innovent currently has 16 innovative drugs on the market, covering major therapeutic areas such as oncology, autoimmune diseases, metabolic disorders, and ophthalmology. The company’s robust product portfolio positions it well to contribute valuable pharmaceutical options to the partnership.
JD Health’s Platform and Reach
JD Health, the medical arm of Chinese e-commerce giant JD.com (NASDAQ: JD), serves a broad user base through its online and offline platforms, including JD Pharmacy and affiliated healthcare institutions. The partnership will utilize these platforms to meet the diverse needs of consumers.
Collaboration Strategy and Focus Areas
The two companies will develop customized supply chain solutions based on the unique characteristics of each drug. Innovent will collaborate with JD Health to implement tailored sales strategies across multiple channels, optimizing drug accessibility. The partnership will focus on weight management and diabetes awareness, encompassing science popularization, medical information dissemination, and professional education. Innovent and JD Health will work with medical experts and institutions to produce and distribute evidence-based health content, utilizing both online and offline channels to enhance public health literacy.-Fineline Info & Tech